Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Nanoparticles that exhibit high epithelial uptake and transepithelial transport More
A novel adjuvant technology for use in vaccines and in antibody production that gives excellent immune responses with low manufacturing costs, and can be administered by a variety of routes More
Methods and formulations for treating or preventing Vascular Cognitive Impairment (VCI) through mucosal administration of E-selectin, an inducible adhesion molecule on endothelial cells More
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. More
NexACT(R) utilizes highly effective, novel excipients or “penetration enhancers” to dramatically improve absorption and bioavailability of drugs. Varying the concentration of the enhancer allows for local or systemic delivery of drug, as desired. More
A method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. More
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms More
immuno-suppresant agent More
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
Compositions and methods for targeted therapeutic release of encapsulated materials from multi functional liposomes at the site of a solid tumor or a diseased site using ionizing and non-ionizing radiation, a process called conformal Intensity Modulated R More
Related Reports
Market Research Reports provided by reports.innovaro.com
Jan 2011 - 124 pages - $1,740
Jan 2010 - $75
Jun 2009 - 118 pages - $1,040
Nov 2009 - 830 pages - $1,040
Dec 2010 - 37 pages - $500
Nov 2010 - 85 pages - $3,500
Jan 2011 - 34 pages - $500
Jun 2009 - 110 pages - $1,040
Nov 2010 - 40 pages - $500
May 2011 - 15 pages - $250
Your selection
Browse By
- Industry sector
- Intravesical
- Nasal
- Nasal topical
- Ophthalmic
- Oral liquid
- Oral solid
- Otic
- Parenteral
- Pulmonary
- Rectal
- Systemic
- Topical
- Vaginal
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us